Buckingham Strategic Partners Tg Therapeutics, Inc. Call Options Transaction History
Buckingham Strategic Partners
- $6.15 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TGTX
# of Institutions
415Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$524 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$383 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$250 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$110 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$95.6 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.88B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...